Final Overall Survival (Os) Analysis Of An International Randomized Trial Evaluating Bevacizumab (Bev) In The Primary Treatment Of Advanced Ovarian Cancer: A Nrg Oncology/Gynecologic Oncology Group (Gog) Study

5517Background: GOG 0218 is a double-blind, placebo-controlled, phase 3 randomized trial studying chemotherapy with and without concurrent BEV, and with concurrent BEV followed by maintenance BEV for advanced stage ovarian carcinoma. In 2010, at a median follow-up of 17.4 months (m), the trial met its primary endpoint demonstrating improvement in progression-free survival (PFS) for patients receiving BEV with and following chemotherapy compared to chemotherapy alone: median PFS 14.1 vs 10.3m, respectively; HR 0.717; 95% CI, 0.625-0.824; p u003c 0.001 [Burger RA, et al N Engl J Med 2011]. With extended follow-up, we report on the key secondary endpoint, final OS. Methods: 1,873 women with newly diagnosed, incompletely resected stage III or stage IV ovarian cancer received six 21-day cycles of carboplatin (AUC 6) IV and paclitaxel (175 mg/m2 BSA) IV chemotherapy alone (control) vs chemotherapy plus BEV (15 mg/kg body weight) IV cycles 2-6 (BEV-initiation) vs chemotherapy plus BEV cycles 2-22 (BEV-throughout). O...